Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05040386
Other study ID # IRB-300007901
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 19, 2022
Est. completion date June 1, 2025

Study information

Verified date March 2024
Source University of Alabama at Birmingham
Contact Jazmine Coffee-Dunning
Phone (205) 996-3679
Email jcdunning@uabmc.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in older Americans. COPD increases in frequency with age, and older adults with COPD often have significant unmet geriatrics-palliative care needs that results in reduced quality of life, high healthcare utilization, and care at the end of life that does not align with the values and wishes of patients and their care partners. Older adults with COPD could benefit from proactive geriatrics-palliative care before the end of life. However, no geriatrics-palliative care interventions have been systematically developed and tested in community-dwelling older adults with COPD and their care partners. As the number of older adults with COPD increases to levels unmatched by current palliative care workforce trends, innovative strategies are desperately needed to improve the delivery of geriatrics-palliative care in COPD before the end of life. Project EPIC (Empowering People to Independence in COPD) is a multiphase study to refine and pilot test the EPIC telephonic nurse coaching intervention in older adults with COPD and their care partners. EPIC is informed by the ENABLE (Educate, Nurture, Advise Before Life Ends) early palliative care intervention that improved quality of life and mood for patients with advanced cancer and has been iteratively refined over decades and rigorous randomized controlled trial testing. In the intervention, palliative care-trained nurse coaches deliver the Charting Your Course Curriculum over the phone to patients (six sessions) and their care partners (four sessions), with activities and monthly telephone follow-up following a manualized curriculum. We conducted a formative evaluation in a diverse and multidisciplinary group of stakeholders to refine ENABLE for patients with COPD and pilot tested the potential feasibility of the refined intervention, EPIC, in patients and their care partners. The current study summatively evaluates EPIC through a hybrid effectiveness-implementation pilot randomized controlled trial in dyads of community-dwelling older adults with moderate to very severe COPD and their care partners randomized to usual COPD care (control) versus usual COPD care + EPIC (intervention). The primary outcomes are trial and intervention feasibility and acceptability. Secondary geriatrics-palliative care outcomes include Life-Space mobility, quality of life, cognitive impairment, functional status, healthcare utilization, palliative care uptake, and care partner burden.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date June 1, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Patients Inclusion criteria (must meet ALL of the following): 1. =60 years; 2. COPD on routinely collected spirometry (FEV1/FVC <0.70 + FEV1<80%); 3. Able to speak English; 4. At least one of the following: 4a) Severe breathlessness as defined by a documented modified Medical Research Council (mMRC) Dyspnea Scale Score >2 in the medical record or any of the following levels of severe breathlessness by medical review: breathless after walking about 100 yards, breathless after a walking few minutes on level ground, or too breathless to leave the house or when dressing); OR, 4b) =1 hospitalization in the year prior but >30 days from enrollment; OR, 4c) On supplemental oxygen (exertional or continuous). Exclusion criteria (can be excluded for ANY of the following): 1. No access to a dedicated telephone service; 2. Recent hospitalization for any reason or exacerbation of COPD in the past 30 days or ongoing exacerbation symptoms requiring treatment with antibiotics and steroids; 3. Treated within the past 60 days for an advanced cancer defined as metastatic and/or recurrent/progressive stage III/IV cancer, including brain, lung, breast, gynecologic, head and neck, gastrointestinal, genitourinary cancer, and hematologic malignancies by self report or chart review; 4. Active schizophrenia, major depressive disorder, bipolar disorder, suicidal ideations, or substance abuse by self-report or chart review (Active means currently being treated for schizophrenia, bipolar disorder, or suicidal ideations or having active and untreated major depressive disorder, i.e. not under the care of a clinician or not on medications such as antidepressants or mood stabilizers, or having active and untreated substance abuse, i.e. not on medication or enrolled in a substance abuse program); 5. Non-correctable hearing impairment (i.e. hearing impairment despite hearing aids); 6. Severe cognitive impairment (score =3 points on 6-item Callahan Screener): a) Correctly identify current year (1 point); b) Correctly identify current month (1 point); c) Correctly identify current day (1 point); d) Correctly recall "apple" after 5 minutes (1 point); e) Correctly recall "table" after 5 minutes (1 point); f) Correctly recall "penny" after 5 minutes (1 point). Care partners Inclusion criteria (must meet ALL of the following): 1. =18 years; 2. Self-reporting as "an unpaid spouse or care partner, relative, or friend who knows [the patient] well and is involved in their medical care"; 3. Able to speak English. Exclusion criteria (can be excluded for ANY of the following): 1. No access to a dedicated telephone service; 2. Active schizophrenia, major depressive disorder, bipolar disorder, suicidal ideation, or substance abuse by self-report (Active schizophrenia, major depressive disorder, bipolar disorder, suicidal ideation, or substance abuse by self-report or chart review (Active means currently being treated for schizophrenia, bipolar disorder, or suicidal ideations or having active and untreated major depressive disorder, i.e. not under the care of a clinician or not on medications such as antidepressants or mood stabilizers, or having active and untreated substance abuse, i.e. not on medication or enrolled in a substance abuse program); 3. Non-correctable hearing impairment (i.e. hearing impairment despite hearing aids); 4. Severe cognitive impairment (score =3 points on a 6-item Callahan screener): a) Correctly identify current year (1 point); b) Correctly identify current month (1 point); c) Correctly identify current day (1 point); d) Correctly recall "apple" after 5 minutes (1 point); e) Correctly recall "table" after 5 minutes (1 point); f) Correctly recall "penny" after 5 minutes (1 point)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
EPIC
Participants randomized to the intervention arm receive usual COPD care + EPIC. EPIC is informed by the ENABLE model or early palliative care. ENABLE (Educate, Nurture, Advise, Before Life Ends) is a theory-based, rigorously tested, and multicomponent early palliative care model that improved quality of life and emotional symptoms in patients with advanced cancer. The PI adapted ENABLE to meet the specific needs of patients with COPD and their care partners through EPIC. EPIC includes a series of weekly telephone-based, nurse coach-led sessions for patients (six) and their care partners (four) aided by a manualized curriculum. Participants also complete activities geared to solving problems and making difficult decisions, attend a Supportive Care clinic visit, and complete advance directives.
Other:
Usual COPD Care
Participants randomized to this arm receive standard of care for COPD. This includes routine clinic visits with their clinician, medications, inhalers, vaccinations, tobacco cessation counseling, illness education, cardiopulmonary rehabilitation, specialist referrals, and other COPD therapies deemed appropriate by their clinician.

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
University of Alabama at Birmingham

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Intervention Feasibility For participants randomized to the intervention arm, we will measure completion of EPICcomponents (CYC sessions and assignments) and tabulate completion rates (# participants completing each component). We will define =80% completion of components as evidence of feasibility. Baseline to 6 months
Primary Trial and Survey Feasibility Rates of screening, enrollment, retention, reasons for exclusion and refusals, and attrition. Survey completion rates will be measured, and survey feasibility will be defined as participants completing =80% of instruments. Baseline to 6 months
Primary Acceptability (Quantitative) Post-intervention survey on intervention acceptability with Likert scale rated 1 to 10; 10 being most acceptable. Overall average score =8 of 10 defined as acceptable. 6 months
Primary Acceptability (Qualitative) Post-intervention semi-structured, in-depth interviews by telephone conducted by study coordinator to explore acceptability, barriers, facilitators, and survey burden. 6 months
Secondary UAB Life Space Assessment (LSA) 15-item measure of Life-Space mobility, or the frequency, distance, and independence of movement in the 4 weeks prior to administration. Scores range from 0-120, and lower scores are associated with more restricted Life-Space mobility. A threshold LSA score of >=60 is used to identify restricted Life-Space mobility, which is a marker of social isolation, frailty, and predictor of healthcare utilization in older adults. We have also demonstrated that restricted Life-Space mobility predicts severe exacerbations of COPD. MCID=5 points with an alpha=0.80. Baseline, 3 months, 6 months
Secondary Chronic Respiratory Questionnaire (CRQ) 20-item measure along domains of dyspnea, fatigue, emotional function, and mastery. Higher scores are associated with better quality of life with an MCID of 0.5 points and an alpha=0.70. Baseline, 3 months, 6 months
Secondary PROMIS Global Health 10 10-item measure with physical and mental health domains; 9 questions are rated on a 5-point Likert-scale, and the 10th question rates pain on a scale of 0 to 10. Raw scores converted to standardized t-scores ranging from 0 to 100, with lower scores associated with worse quality of life. Baseline, 3 months, 6 months
Secondary Montgomery Borgatta Caregiver Burden 14-item measure of care partner burden along domains of objective burden (alpha=0.87-0.90), subjective demand burden (alpha =0.68-0.82), and subjective stress burden (alpha=0.81-0.88). Higher scores are associated with greater burden. Baseline, 3 months, 6 months
Secondary Hospital Anxiety and Depression Scale (HADS) 14-item measure of emotional symptoms with a 7-item anxiety subscale and a 7-item depression subscale. Each question has a 4-point Likert scale, and scores from 0-21 per subscale, with higher scores associated with more severe anxiety and depressive symptoms. A subscale score >=8 on each subscale is the accepted threshold for clinically-elevated anxiety or depressive symptoms. The minimal clinically important difference is 1.5 points on each subscale with an alpha=0.82-0.83. Baseline, 3 months, 6 months
Secondary Modified Telephone Interview for Cognitive Status (mTICS) 14-item measure of cognitive impairment, which has been validated in COPD. Scores range from 0-50 with higher scores associated with more cognitive impairment. Validated over telephone (alpha=0.80). Baseline, 3 months, 6 months
Secondary Katz Index of Activities of Daily Living 6-item measure of independence in activities. Range 0-6. Higher scores associated with more independence; MCID=0.47. Baseline, 3 months, 6 months
Secondary Lawton Instrumental Activities of Daily Living 8-item measure of functioning in independent living. MCID=0.47; Higher scores associated with higher functioning. alpha=0.85 Baseline, 3 months, 6 months
Secondary Healthcare and palliative care utilization Rates of emergency room visits, hospitalizations, intensive care unit admissions, imaging, procedures, palliative care, hospice, change in code status, advance directive completion, identified surrogate decision maker, goals of care documentation 6 months
Secondary De Jon Gierveld Loneliness Scale 6-item measure of loneliness. Alpha=0.88. Baseline, 3 months, 6 months
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT06000696 - Healthy at Home Pilot
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Completed NCT04105075 - COPD in Obese Patients
Recruiting NCT05825261 - Exploring Novel Biomarkers for Emphysema Detection
Active, not recruiting NCT04075331 - Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial Phase 2/Phase 3
Terminated NCT03640260 - Respiratory Regulation With Biofeedback in COPD N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
Withdrawn NCT04210050 - Sleep Ventilation for Patients With Advanced Hypercapnic COPD N/A
Terminated NCT03284203 - Feasibility of At-Home Handheld Spirometry N/A
Recruiting NCT06110403 - Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness Phase 1/Phase 2
Active, not recruiting NCT06040424 - Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Recruiting NCT04868357 - Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program N/A
Completed NCT01892566 - Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV N/A
Completed NCT04119856 - Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD N/A
Completed NCT04485741 - Strados System at Center of Excellence
Completed NCT03626519 - Effects of Menthol on Dyspnoea in COPD Patients N/A
Recruiting NCT04860375 - Multidisciplinary Management of Severe COPD N/A